Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC010 in Advanced Solid Tumors
NCT06307925Phase 1Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC010 in solid tumor (advanced stage) (2 arms). Primary endpoints: Incidence of Dose-Limiting Toxicity at 28 days, Adverse Events at 2 years and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
HC010
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06307925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307925.